Castle Biosciences Inc financial data

Symbol
CSTL on Nasdaq
Location
505 S Friendswood Drive, Suite 401, Friendswood, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 772 % +0.63%
Quick Ratio 16.5 % -12.9%
Debt-to-equity 16.7 % +15.6%
Return On Equity -2.11 % -173%
Return On Assets -1.81 % -167%
Operating Margin -6.66 % -21.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29M shares +4.58%
Common Stock, Shares, Outstanding 29M shares +4.58%
Entity Public Float 587M USD +88.7%
Weighted Average Number of Shares Outstanding, Basic 28.9M shares +4.59%
Weighted Average Number of Shares Outstanding, Diluted 29.5M shares +2.81%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 346M USD +20.4%
Cost of Revenue 65.8M USD +26.2%
Research and Development Expense 49.5M USD -8.15%
Operating Income (Loss) -23.1M USD -46.3%
Income Tax Expense (Benefit) -781K USD +14.9%
Net Income (Loss) Attributable to Parent -9.47M USD -205%
Earnings Per Share, Basic 0 USD/shares -182%
Earnings Per Share, Diluted 0 USD/shares -192%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 82.2M USD -3.9%
Marketable Securities, Current 194M USD
Accounts Receivable, after Allowance for Credit Loss, Current 52.3M USD +13.7%
Inventory, Net 8.37M USD +4.41%
Assets, Current 349M USD +8.82%
Property, Plant and Equipment, Net 22.3M USD +70.6%
Operating Lease, Right-of-Use Asset 15.5M USD +33.4%
Goodwill 10.7M USD 0%
Other Assets, Noncurrent 1.24M USD -53.7%
Assets 545M USD +11.8%
Accounts Payable, Current 13.2M USD +38.2%
Employee-related Liabilities, Current 25M USD +17.6%
Liabilities, Current 50.9M USD +29%
Deferred Income Tax Liabilities, Net 3.13M USD
Operating Lease, Liability, Noncurrent 25.4M USD +86%
Other Liabilities, Noncurrent 16K USD -70.9%
Liabilities 89.4M USD +40.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 39K USD
Retained Earnings (Accumulated Deficit) -221M USD -4.47%
Stockholders' Equity Attributable to Parent 455M USD +7.43%
Liabilities and Equity 545M USD +11.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.04M USD +11.7%
Net Cash Provided by (Used in) Financing Activities -1.55M USD -115%
Net Cash Provided by (Used in) Investing Activities -22.4M USD -13.9%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 29M shares +4.58%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -30M USD -88.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82.2M USD -3.9%
Deferred Tax Assets, Valuation Allowance 50.5M USD -8.16%
Deferred Tax Assets, Gross 73.2M USD -7.9%
Operating Lease, Liability 16M USD +4.57%
Depreciation 5.59M USD +38%
Payments to Acquire Property, Plant, and Equipment 4.74M USD -48.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.26M USD -196%
Lessee, Operating Lease, Liability, to be Paid 22.8M USD -6.39%
Operating Lease, Liability, Current 1.57M USD +28.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.4M USD +6.58%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.95M USD +26.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -770K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.75M USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.44M USD +9.26%
Deferred Tax Assets, Operating Loss Carryforwards 31.8M USD -32.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.49M USD +1.51%
Additional Paid in Capital 677M USD +6.41%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 36.9M USD +308%
Depreciation, Depletion and Amortization 29.8M USD +791%
Deferred Tax Assets, Net of Valuation Allowance 22.7M USD -7.32%
Share-based Payment Arrangement, Expense 46.9M USD -7.59%
Interest Expense 9K USD -95.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%